Helius stock rises on expanded approval of Neuromodulation Stimulator in Canada
Bill Oxford
- Helius Medical Technologies (NASDAQ:HSDT) said Health Canada approved the expanded use of Portable Neuromodulation Stimulator (PoNS) as a short term therapy (14 weeks) of gait (walking) deficit due to mild and moderate symptoms from stroke, along with physical therapy.
- The company noted that PoNS is already approved in Canada for use as a short term therapy for chronic balance deficit due to mild to moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from multiple sclerosis (MS).
- "Improvement of gait ability represents an important milestone in the rehabilitation of stroke patients and translates into meaningful therapeutic outcomes, such as decreasing the risk of falling," said Helius' Chief Medical Officer Antonella Favit-Van Pelt.
- The company noted that real-world evidence data showed that patients with mild and moderate stroke using PoNS, experienced betterment of their gait averaging a 6.74-point improvement in the functional gait assessment score over 14 weeks of treatment.
- HSDT +7.57% to $0.31 premarket March 9